Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients

Transplantation

Volumn 74, Issue 7, 2002, Pages 1000-1006

  Berney, Thierry ^a,b   Delis, Spiros ^a   Kato, Tomoaki ^a   Nishida, Seigo ^a   Mittal, Naveen K ^a   Madariaga, Juan ^a   Levi, David ^a   Nery, Jose R ^a   Cirocco, Robert E ^a   Gelman, Barry ^a   Ruiz, Philip ^a   Tzakis, Andreas G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD20 ANTIGEN; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OKT 3; ORTHOCLONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RECIPIENT; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037109021     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210150-00018     Document Type: Article

References (46)

1. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984; 1(8377): 583.
2. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 1999; 68: 1517.
3. Nalesnik MA, Starzl TE. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci 1994; 4: 61.
4. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052.
5. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999; 67: 990.
6. Cacciarelli TV, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998; 66: 1047.
7. Rubin RH, Fishman JA. Infection in the organ transplant recipient. In: Ginns LC, Cosimi AB, Morris PJ, eds. Transplantation. Oxford, Blackwell Science 1999, p 747.
8. Grant D. Intestinal transplantation: 1997 report of the international registry. Intestinal Transplant Registry. Transplantation 1999; 67: 1061.
9. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg 2001; 234: 404.
10. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457.
11. Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1: 1.
12. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27(suppl 12): 79.
13. Cook RC, Connors JM, Gascoyne RD, et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999; 354: 1698.
14. Niedermeyer J, Hoffmeyer F, Hertenstein B, et al. Treatment of lymphoproliferative disease with rituximab. Lancet 2000; 355: 499.
15. Oertel SH, Anagnostopoulos I, Bechstein WH, et al. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 2000; 69: 430.
16. Zompi S, Tulliez M, Conti F, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal proliferative disorders after orthotopic liver transplantation: a report of 3 cases. J Hepatol 2000; 32: 521.
17. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000 (suppl 1); 11: 113.
18. Reynaud-Gaubert M, Stoppa AM, Gaubert J, et al. Anti-CD20 monoclonal antibody therapy in Epstein-Barr virus-associated B cell lymphoma following lung transplantation. J Heart Lung Transplant 2000; 19: 492.
19. Zilz ND, Olson DJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplant. J Heart Lung Transplant 2001; 20: 770.
20. Tzakis AG, Kato T, Nishida S, et al. Evolution of gastrointestinal transplantation at the University of Miami. Transplant Proc 2001; 33: 1545.
21. Sioutos N, Bagg A, Michaud GY, et al. Polymerase chain reaction versus Southern blot hybridization: detection of immunoglobulin heavy-chain gene rearrangement. Diagn Mol Pathol 1995; 4: 8.
22. Rowe M, Young LS, Crocker J, et al. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphoma in man. J Exp Med 1991; 173: 147.
23. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520.
24. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implication for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381.
25. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997; 14: 2.
26. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 1851.
27. Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97.
28. Oertel SH, Ruhnke MS, Anagnostopoulos I, et al. Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 1999; 67: 765.
29. Praghakaran K, Wise B, Chen A, et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 1999; 34: 112.
30. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333.
31. McCarthy M, Ramage J, McNair A, et al. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol 1997; 27: 1015.
32. Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66: 1770.
33. Comoli P, Labirio M, Bassi S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592.
34. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438.
35. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137.
36. Langnas AN, Shaw BW Jr, Antonson DL, et al. Preliminary experience with intestinal transplantation in infants and children. Pediatrics 1996; 97: 443.
37. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 619.
38. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135.
39. Maeda T, Yamada Y, Tawara M, et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol 2001; 74: 70.
40. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055.
41. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611.
42. Schmitz K, Brugger W, Weiss B, et al. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999; 106: 571.
43. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1998; 18: 465.
44. Babel N, Schwarzmann F, Prang N, et al. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation 2001; 72: 736.
45. Schambeck CM, Bedel A, Keller F. Limit of quantification (functional sensitivity) of the new IMx tacrolimus II microparticle enzyme immunoassay. Clin Chem 1998; 44: 2217.
46. Schaar CG, van der Pijl JW, van Hoek B, et al. Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder. Transplantation 2001; 71: 47.